TriangleSotorasib (NCT06582771)
Sotorasib trial for Non Small Lung Cancer (NCT06582771). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or recurrent non-small-cell lung cancer carrying KRAS G12C, without prior treatment for advanced disease. They must decline first-line chemotherapy or immunotherapy, or have progressed after earlier-stage systemic treatment.
The idea: sotorasib blocks KRAS G12C signals that support cancer growth. Participants take 960 milligrams by mouth daily. Researchers measure tumor responses. Biopsies are planned before treatment and on days seven to 21, with an exception if unsafe.
This phase 2 study plans 39 patients. Memorial Sloan Kettering sponsors it; seven US sites are recruiting, including New York.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.